ALK c.3607G>A ;(p.D1203N)

Variant ID: 2-29443610-C-T

NM_004304.4(ALK):c.3607G>A;(p.D1203N)

This variant was identified in 127 publications

View GRCh38 version.




Publications:


EML4-ALK biology and drug resistance in Non-Small Cell Lung Cancer: a new phase of discoveries.

Molecular Oncology
Elshatlawy, Mariam M; Sampson, Josephina J; Clarke, Katy K; Bayliss, Richard R
Publication Date: 2023-05-07

Variant appearance in text: ALK: D1203N
PubMed Link: 37149843
Variant Present in the following documents:
  • Main text
  • MOL2-17-950.pdf
View BVdb publication page



Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.

Nature Communications
Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP
Publication Date: 2023-05-05

Variant appearance in text: ALK: D1203N
PubMed Link: 37147298
Variant Present in the following documents:
  • Main text
  • 41467_2023_Article_38195.pdf
  • 41467_2023_38195_MOESM3_ESM.xlsx, sheet 1
View BVdb publication page



Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.

Investigational New Drugs
Yang, Yingying Y; Zheng, Qingmei Q; Wang, Xinmei X; Zhao, Shuyong S; Huang, Wenshu W; Jia, Linchao L; Ma, Cuicui C; Liu, Shicong S; Zhang, Yongpeng Y; Xin, Qianqian Q; Sun, Yan Y; Zheng, Shansong S
Publication Date: 2023-04-10

Variant appearance in text: ALK: D1203N
PubMed Link: 37036582
Variant Present in the following documents:
  • Main text
  • 10637_2023_Article_1350.pdf
View BVdb publication page



Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.

International Journal Of Molecular Sciences
Cheon, So Yeong SY; Kwon, Sunghark S
Publication Date: 2023-03-18

Variant appearance in text: ALK: D1203N
PubMed Link: 36982897
Variant Present in the following documents:
  • Main text
  • ijms-24-05821.pdf
View BVdb publication page



Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.

Journal Of Thoracic Disease
Ma, Yuxiang Y; Pan, Hui H; Liu, Yu Y; Zhang, Yang Y; Hong, Shaodong S; Huang, Jianjin J; Weng, Shanshan S; Yang, Yunpeng Y; Fang, Wenfeng W; Huang, Yan Y; Xiao, Shanshan S; Wang, Tao T; Ding, Lieming L; Cui, Lingling L; Zhang, Li L; Zhao, Hongyun H
Publication Date: 2022-12

Variant appearance in text: ALK: D1203N
PubMed Link: 36647478
Variant Present in the following documents:
  • Main text
  • jtd-14-12-4751.pdf
View BVdb publication page



Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.

Molecular Biomedicine
Wang, Zixi Z; Xing, Yurou Y; Li, Bingjie B; Li, Xiaoyu X; Liu, Bin B; Wang, Yongsheng Y
Publication Date: 2022-12-12

Variant appearance in text: ALK: D1203N
PubMed Link: 36508072
Variant Present in the following documents:
  • Main text
  • 43556_2022_Article_107.pdf
View BVdb publication page



Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma.

Frontiers In Oncology
Pasau, Thomas T; Wauters, Els E; Wauters, Isabelle I; Duplaquet, Fabrice F; Pirard, Lionel L; Pop-Stanciu, Claudia C; D'Haene, Nicky N; Dupont, Michael M; Vander Borght, Thierry T; Rondelet, Benoît B; Ocak, Sebahat S
Publication Date: 2022

Variant appearance in text: ALK: D1203N
PubMed Link: 36419902
Variant Present in the following documents:
  • Main text
  • fonc-12-985446.pdf
View BVdb publication page



Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria.

American Journal Of Human Genetics
Pejaver, Vikas V; Byrne, Alicia B AB; Feng, Bing-Jian BJ; Pagel, Kymberleigh A KA; Mooney, Sean D SD; Karchin, Rachel R; O'Donnell-Luria, Anne A; Harrison, Steven M SM; Tavtigian, Sean V SV; Greenblatt, Marc S MS; Biesecker, Leslie G LG; Radivojac, Predrag P; Brenner, Steven E SE; ,
Publication Date: 2022-12-01

Variant appearance in text: ALK: D1203N; rs759845895
PubMed Link: 36413997
Variant Present in the following documents:
  • mmc3.xlsx, sheet 1
View BVdb publication page



The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Cancers
Cognigni, Valeria V; Pecci, Federica F; Lupi, Alessio A; Pinterpe, Giada G; De Filippis, Chiara C; Felicetti, Cristiano C; Cantini, Luca L; Berardi, Rossana R
Publication Date: 2022-09-29

Variant appearance in text: ALK: D1203N
PubMed Link: 36230686
Variant Present in the following documents:
  • Main text
  • cancers-14-04765.pdf
View BVdb publication page



Molecular targeted therapy for anticancer treatment.

Experimental & Molecular Medicine
Min, Hye-Young HY; Lee, Ho-Young HY
Publication Date: 2022-10

Variant appearance in text: ALK: D1203N
PubMed Link: 36224343
Variant Present in the following documents:
  • Main text
  • 12276_2022_Article_864.pdf
View BVdb publication page



Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Journal Of Hematology & Oncology
Wu, Qing Q; Qian, Wei W; Sun, Xiaoli X; Jiang, Shaojie S
Publication Date: 2022-10-08

Variant appearance in text: ALK: D1203N
PubMed Link: 36209184
Variant Present in the following documents:
  • Main text
  • 13045_2022_Article_1362.pdf
View BVdb publication page



Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.

Bmc Cancer
Wu, Huita H; Ji, Haonan H; Yang, Wenhui W; Zhang, Min M; Guo, Yifang Y; Li, Bangkai B; Wang, Jiayin J; Chen, Rongrong R; Chen, Yuan Y; Wang, Xin X
Publication Date: 2022-09-27

Variant appearance in text: ALK: D1203N
PubMed Link: 36167530
Variant Present in the following documents:
  • 12885_2022_9922_MOESM5_ESM.xlsx, sheet 1
View BVdb publication page



Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.

Signal Transduction And Targeted Therapy
Yang, Yang Y; Li, Shuo S; Wang, Yujiao Y; Zhao, Yi Y; Li, Qiu Q
Publication Date: 2022-09-17

Variant appearance in text: ALK: D1203N
PubMed Link: 36115852
Variant Present in the following documents:
  • Main text
  • 41392_2022_Article_1168.pdf
View BVdb publication page



AACR Project GENIE: 100,000 Cases and Beyond.

Cancer Discovery
Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,
Publication Date: 2022-09-02

Variant appearance in text: ALK: D1203N
PubMed Link: 35819403
Variant Present in the following documents:
  • cd-21-1547_supplementary_table_1_suppst1.xlsx, sheet 1
View BVdb publication page



Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.

Frontiers In Oncology
Shen, Fangfang F; Liang, Naixin N; Fan, Zaiwen Z; Zhao, Min M; Kang, Jing J; Wang, Xifang X; Hu, Qun Q; Mu, Yongping Y; Wang, Kai K; Yuan, Mingming M; Chen, Rongrong R; Guo, Wei W; Dong, Guilan G; Zhao, Jun J; Bai, Jun J
Publication Date: 2022

Variant appearance in text: ALK: 3607G>A; D1203N
PubMed Link: 35814426
Variant Present in the following documents:
  • DataSheet_1.xlsx, sheet 2
View BVdb publication page



Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC.

Cell Death Discovery
Lu, Conghua C; Yu, Rui R; Zhang, Chong C; Lin, Caiyu C; Dou, Yuanyao Y; Wu, Di D; Pan, Yonghong Y; Peng, Tao T; Tang, Huan H; Han, Rui R; He, Yong Y
Publication Date: 2022-04-22

Variant appearance in text: ALK: D1203N
PubMed Link: 35459209
Variant Present in the following documents:
  • 41420_2022_Article_1027.pdf
View BVdb publication page



Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.

Cancer Medicine
Kwon, Minsuk M; Ku, Bo Mi BM; Olsen, Steve S; Park, Sehhoon S; Lefterova, Martina M; Odegaard, Justin J; Jung, Hyun-Ae HA; Sun, Jong-Mu JM; Lee, Se-Hoon SH; Ahn, Jin Seok JS; Park, Keunchil K; Ahn, Myung-Ju MJ
Publication Date: 2022-08

Variant appearance in text: ALK: D1203N
PubMed Link: 35437925
Variant Present in the following documents:
  • CAM4-11-2944-s002.xlsx, sheet 1
View BVdb publication page



Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.

Cancers
Descourt, Renaud R; Pérol, Maurice M; Rousseau-Bussac, Gaëlle G; Planchard, David D; Mennecier, Bertrand B; Wislez, Marie M; Cadranel, Jacques J; Cortot, Alexis Benjamin AB; Guisier, Florian F; Galland, Loïck L; Do, Pascal P; Schott, Roland R; Dansin, Éric É; Arrondeau, Jennifer J; Auliac, Jean-Bernard JB; Geier, Margaux M; Chouaïd, Christos C
Publication Date: 2022-03-30

Variant appearance in text: ALK: D1203N
PubMed Link: 35406523
Variant Present in the following documents:
  • Main text
  • cancers-14-01751.pdf
View BVdb publication page



Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.

Frontiers In Oncology
Wang, Yuan Y; He, Jing J; Xu, Manyu M; Xue, Qingfeng Q; Zhu, Cindy C; Liu, Juan J; Zhang, Yaping Y; Shi, Wenyu W
Publication Date: 2022

Variant appearance in text: ALK: D1203N
PubMed Link: 35211406
Variant Present in the following documents:
  • Main text
  • fonc-12-815654.pdf
View BVdb publication page



Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.

Esmo Open
Hua, G G; Zhang, X X; Zhang, M M; Wang, Q Q; Chen, X X; Yu, R R; Bao, H H; Liu, J J; Wu, X X; Shao, Y Y; Liang, B B; Lu, K K
Publication Date: 2022-02

Variant appearance in text: ALK: D1203N
PubMed Link: 35123209
Variant Present in the following documents:
  • Main text
  • main.pdf
View BVdb publication page



Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.

Esmo Open
Hua, G G; Zhang, X X; Zhang, M M; Wang, Q Q; Chen, X X; Yu, R R; Bao, H H; Liu, J J; Wu, X X; Shao, Y Y; Liang, B B; Lu, K K
Publication Date: 2022-02-02

Variant appearance in text: ALK: D1203N
PubMed Link: 35123209
Variant Present in the following documents:
  • Main text
  • main.pdf
View BVdb publication page



Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.

Translational Cancer Research
Vavalà, Tiziana T; Mariniello, Annapaola A; Novello, Silvia S
Publication Date: 2019-01

Variant appearance in text: ALK: D1203N
PubMed Link: 35117063
Variant Present in the following documents:
  • Main text
  • tcr-08-S1-S48.pdf
View BVdb publication page



Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.

Medcomm
Cheng, Yuan Y; Zhang, Tao T; Xu, Qing Q
Publication Date: 2021-12

Variant appearance in text: ALK: D1203N
PubMed Link: 34977873
Variant Present in the following documents:
  • Main text
  • MCO2-2-692.pdf
View BVdb publication page



Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers
Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD
Publication Date: 2021-11-29

Variant appearance in text: ALK: D1203N
PubMed Link: 34885113
Variant Present in the following documents:
  • Main text
  • cancers-13-06003.pdf
View BVdb publication page



Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL.

Cancers
Hare, Lucy L; Burke, G A Amos GAA; Turner, Suzanne D SD
Publication Date: 2021-11-29

Variant appearance in text: ALK: D1203N
PubMed Link: 34885113
Variant Present in the following documents:
  • Main text
  • cancers-13-06003.pdf
View BVdb publication page



Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras.

Medcomm
Song, Xiaoling X; Zhong, Hui H; Qu, Xiaojuan X; Yang, Linsong L; Jiang, Biao B
Publication Date: 2021-09

Variant appearance in text: ALK: D1203N
PubMed Link: 34766150
Variant Present in the following documents:
  • Main text
  • MCO2-2-341.pdf
View BVdb publication page



New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.

Cancers
Villa, Matteo M; Sharma, Geeta G GG; Manfroni, Chiara C; Cortinovis, Diego D; Mologni, Luca L
Publication Date: 2021-10-14

Variant appearance in text: ALK: D1203N
PubMed Link: 34680298
Variant Present in the following documents:
  • Main text
View BVdb publication page



The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

Frontiers In Oncology
Pan, Yue Y; Deng, Chao C; Qiu, Zhenhua Z; Cao, Chenghui C; Wu, Fang F
Publication Date: 2021

Variant appearance in text: ALK: D1203N
PubMed Link: 34660278
Variant Present in the following documents:
  • Main text
  • fonc-11-713530.pdf
View BVdb publication page



Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.

Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
Publication Date: 2021

Variant appearance in text: ALK: D1203N
PubMed Link: 34630336
Variant Present in the following documents:
  • Table_1.xlsx, sheet 2
View BVdb publication page



A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.

Jto Clinical And Research Reports
Zhu, Viola W VW; Nagasaka, Misako M; Madison, Russell R; Schrock, Alexa B AB; Cui, Jean J; Ou, Sai-Hong Ignatius SI
Publication Date: 2021-01

Variant appearance in text: ALK: D1203N
PubMed Link: 34589977
Variant Present in the following documents:
  • Main text
  • main.pdf
View BVdb publication page



Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.

Biomedicines
Palacín-Aliana, Irina I; García-Romero, Noemí N; Asensi-Puig, Adrià A; Carrión-Navarro, Josefa J; González-Rumayor, Víctor V; Ayuso-Sacido, Ángel Á
Publication Date: 2021-07-28

Variant appearance in text: ALK: D1203N
PubMed Link: 34440110
Variant Present in the following documents:
  • Main text
View BVdb publication page



Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report.

Oncotargets And Therapy
Yao, Bin B; Han, Xue X; Pang, Linrong L; Xu, Caihong C; Liu, Sisi S; Cheng, Xiaochun X; Chen, Jun J
Publication Date: 2021

Variant appearance in text: ALK: D1203N
PubMed Link: 34376997
Variant Present in the following documents:
  • Main text
  • ott-14-4329.pdf
View BVdb publication page



Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Translational Oncology
Ou, Sai-Hong Ignatius SI; Nagasaka, Misako M; Brazel, Danielle D; Hou, Yujie Y; Zhu, Viola W VW
Publication Date: 2021-11

Variant appearance in text: ALK: D1203N
PubMed Link: 34365220
Variant Present in the following documents:
  • Main text
View BVdb publication page



One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.

The Oncologist
Lee, Youngjoo Y; Cho, Youngnam Y; Park, Eun Young EY; Park, Seong-Yun SY; Hwang, Kum Hui KH; Han, Ji-Youn JY
Publication Date: 2021-10

Variant appearance in text: ALK: D1203N
PubMed Link: 34272914
Variant Present in the following documents:
  • ONCO-26-e1683-s002.pdf
View BVdb publication page



TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.

Molecular Cancer Therapeutics
Murray, Brion W BW; Zhai, Dayong D; Deng, Wei W; Zhang, Xin X; Ung, Jane J; Nguyen, Vivian V; Zhang, Han H; Barrera, Maria M; Parra, Ana A; Cowell, Jessica J; Lee, Dong J DJ; Aloysius, Herve H; Rogers, Evan E
Publication Date: 2021-09

Variant appearance in text: ALK: D1203N
PubMed Link: 34158340
Variant Present in the following documents:
  • Main text
  • 1499.pdf
View BVdb publication page



An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance.

Bosnian Journal Of Basic Medical Sciences
Patcas, Adela A; Chis, Ana Florica AF; Militaru, Claudia Florentina CF; Bordea, Ioana Roxana IR; Rajnoveanu, Ruxandra R; Coza, Ovidiu Florin OF; Hanna, Reem R; Tiberiu, Tamas T; Todea, Doina Adina DA
Publication Date: 2022-02-01

Variant appearance in text: ALK: D1203N
PubMed Link: 34082691
Variant Present in the following documents:
  • Main text
  • BJBMS-22-1.pdf
View BVdb publication page



Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.

International Journal Of Molecular Sciences
Ferreira, Daniela D; Miranda, Juliana J; Martins-Lopes, Paula P; Adega, Filomena F; Chaves, Raquel R
Publication Date: 2021-04-07

Variant appearance in text: ALK: D1203N
PubMed Link: 33916986
Variant Present in the following documents:
  • Main text
View BVdb publication page



Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Nature Communications
Mizuta, Hayato H; Okada, Koutaroh K; Araki, Mitsugu M; Adachi, Jun J; Takemoto, Ai A; Kutkowska, Justyna J; Maruyama, Kohei K; Yanagitani, Noriko N; Oh-Hara, Tomoko T; Watanabe, Kana K; Tamai, Keiichi K; Friboulet, Luc L; Katayama, Kazuhiro K; Ma, Biao B; Sasakura, Yoko Y; Sagae, Yukari Y; Kukimoto-Niino, Mutsuko M; Shirouzu, Mikako M; Takagi, Satoshi S; Simizu, Siro S; Nishio, Makoto M; Okuno, Yasushi Y; Fujita, Naoya N; Katayama, Ryohei R
Publication Date: 2021-02-24

Variant appearance in text: ALK: D1203N
PubMed Link: 33627640
Variant Present in the following documents:
  • Main text
View BVdb publication page



Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.

Therapeutic Advances In Medical Oncology
Frost, Nikolaj N; Christopoulos, Petros P; Kauffmann-Guerrero, Diego D; Stratmann, Jan J; Riedel, Richard R; Schaefer, Monica M; Alt, Jürgen J; Gütz, Sylvia S; Christoph, Daniel C DC; Laack, Eckart E; Faehling, Martin M; Fischer, Richard R; Fenchel, Klaus K; Haen, Sebastian S; Heukamp, Lukas L; Schulz, Christian C; Griesinger, Frank F
Publication Date: 2021

Variant appearance in text: ALK: D1203N
PubMed Link: 33613692
Variant Present in the following documents:
  • Main text
View BVdb publication page



Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer.

Cancers
Smolle, Elisabeth E; Taucher, Valentin V; Lindenmann, Joerg J; Jost, Philipp J PJ; Pichler, Martin M
Publication Date: 2021-02-09

Variant appearance in text: ALK: D1203N
PubMed Link: 33572278
Variant Present in the following documents:
  • cancers-13-00699.pdf
View BVdb publication page